Clinical Trial

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated May 27, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Randomized, Double-blind, Controlled, Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Intramuscular Injection of Recombinant Human Anti-tetanus toxin Monoclonal Antibody Injection in Healthy Participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-27.
Trial Details
NCT Number NCT07149454
Lead Sponsor Lanzhou Institute of Biological Products Co., Ltd
Conditions Tetanus
Enrollment 68 participants
Start Date 2025-08-18
Primary Completion 2026-05-27 (estimated)
Study Completion 2026-06-24 (estimated)
Updated on ClinicalTrials.gov 2026-01-28